Athena Athena

X

Digital content for EpicentRx

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
EpicentRx
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
11099 North Torrey Pines Road, Suite 160 La Jolla, CA 92037
Telephone
Telephone
(858) 947-6635
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

https://www.prnewswire.com/news-releases/united-states-adopted-name-usan-council-and-international-nonproprietary-names-inn-expert-committee-recognizes-new-therapeutic-class-by-granting-nibrozetone-as-new-generic-name-for-epicentrxs-lead-small-molecule-nlrp3-inhib-301871261.html

PR NEWSWIRE
06 Jul 2023

https://www.prnewswire.com/news-releases/epicentrx-presents-updates-on-its-oncology-clinical-development-programs-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting-301841594.html

PR NEWSWIRE
02 Jun 2023

https://www.prnewswire.com/news-releases/epicentrx-receives-fast-track-designation-from-the-us-fda-for-lead-asset-rrx-001-to-preventattenuate-chemotherapy-and-radiation-treatment-induced-severe-oral-mucositis-301784214.html

PR NEWSWIRE
29 Mar 2023

https://www.prnewswire.com/news-releases/promising-safety-and-efficacy-signals-from-a-small-phase-1-pilot-study-primetime-with-rrx-001--opdivo-nivolumab-in-traditionally-checkpoint-inhibitor-non-responsive-tumors-301773049.html

PR NEWSWIRE
15 Mar 2023

https://www.prnewswire.com/news-releases/epicentrx-announces-presentation-for-phase-2-randomized-active-controlled-multicenter-trial-to-assess-the-safety-and-efficacy-of-rrx-001-vs-regorafenib-in-thirdfourth-line-colorectal-cancer-at-the-2023-american-society-of-clin-301726884.html

PR NEWSWIRE
20 Jan 2023

https://www.fiercebiotech.com/biotech/eyeing-untapped-niche-epicentrx-makes-case-cancer-toxicity-prevention-drug

Nick Paul Taylor FIERCE BIOTECH
20 Jan 2023

https://www.prnewswire.com/news-releases/epicentrx-publishes-phase-2-results-for-rrx-001-as-an-anti-mucositis-agent-in-patients-receiving-radiation-for-head-and-neck-cancers-301726334.html

PR NEWSWIRE
19 Jan 2023

https://www.prnewswire.com/news-releases/rrx-001--irinotecan-significantly-improved-progression-free-survival-pfs-versus-regorafenib-in-the-randomized-phase-2-rocket-trial-in-advanced-colorectal-cancer-301702337.html

PRNEWSWIRE
14 Dec 2022

https://www.prnewswire.com/news-releases/epicentrx-announces-patent-issued-for-radiation-protection-with-rrx-001-in-combination-regimens-301695211.html

PRNEWSWIRE
06 Dec 2022

https://www.prnewswire.com/news-releases/epicentrx-awarded-funding-from-fightmnd-to-evaluate-therapeutic-potential-of-rrx-001-in-motor-neuron-disease-aka-als-301688321.html

PRNEWSWIRE
29 Nov 2022
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY